공고 • Jul 23
Serina Therapeutics, Inc. Announces Appointment of Farrell Simon to Board of Directors and Board Committees, Effective July 22, 2026 Serina Therapeutics, Inc. had announced the appointment of Farrell Simon, Pharm. D., to the Company's Board of Directors, effective July 22, 2026. Dr. Simon had also been appointed to serve as a member of the Audit Committee and Compensation Committee. Dr. Simon is a biotech, pharmaceutical and consumer health executive with expertise in commercial strategy, operations, and business development. He currently serves as Chief Commercial Officer at Trevi Therapeutics, Inc., where he leads commercial strategy, lifecycle management, and pre-commercial readiness planning. He also leads business development efforts for potential partnerships and M&A. During his tenure at Trevi, he helped engage Trevi's investor base and supported financings totaling more than $400 million from top-tier investors including Frazier, Vivo, Venrock, and Viking. Prior to Trevi, Dr. Simon spent a decade at Pfizer in a series of senior commercial and strategic leadership roles, including Biopharma Chief of Staff and global commercial leadership positions supporting major brands and pipeline assets. He holds a Doctor of Pharmacy degree and an MBA, with a concentration in Finance, from the University of Florida. 공고 • Jul 09
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson’s Disease Serina Therapeutics, Inc. announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease. Following review of initial 72-hour safety and tolerability observations from the sentinel dosing group, the study’s independent Safety Monitoring Committee recommended that dosing continue in the remainder of Cohort 1. Additional patient dosing in Cohort 1 is now underway across sites in the United States and Australia. Serina previously guided that completion of enrollment and dosing in Cohort 1 was expected by the end of the third quarter of 2026. Based on current site activity and patient screening and dosing, the Company now expects to complete enrollment and dosing of Cohort 1 ahead of that timeline, subject to continued trial execution. The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b registrational trial with single-ascending-dose and multiple-ascending-dose components in adults with Parkinson’s disease and motor fluctuations. The study is designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation is overseen by a Safety Monitoring Committee, and the study is being conducted across sites in Australia and the United States, with plans to bring on sites in South Korea and Taiwan as the study advances through subsequent cohorts. The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by an independent Safety Monitoring Committee, and the study is being conducted across sites in the United States, Australia with plans to South Korea and Taiwan. Serina’s proprietary POZ technology is based on a synthetic, water-soluble, low viscosity polymer called poly (2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations. SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Board Change • May 20
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Richard Marshall is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공고 • Apr 21
Serina Therapeutics, Inc., Annual General Meeting, Jun 17, 2026 Serina Therapeutics, Inc., Annual General Meeting, Jun 17, 2026. 공고 • Apr 08
Serina Therapeutics, Inc Announces Novel Lipid Nanoparticles Built On POZ Platform Serina Therapeutics, Inc. announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting at the 5th LNP Formulation & Process Development Summit in Boston, MA. Entitled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform", Dr. Moreadith will present data demonstrating the POZ-lipid in Serina’s platform failed to elicit an antibody response to the polymer in a vaccine format in the rat. The standard PEG-lipid in most LNP formulations elicits a prompt IgM and IgG response and has been shown to be associated with serious adverse events in some individuals. The Serina LNP Laboratory is also advancing an additional replacement strategy targeting ionizable lipids, another essential LNP component that has been implicated in safety concerns. Preliminary results from Serina’s studies of a novel polymer-lipid designed to bind a broad range of oligonucleotide payloads will also be featured in the presentation, underscoring the company’s commitment to improving both the safety and versatility of LNP-based therapeutics. 
